CA3145993A1 - Solid-state forms of relugolix - Google Patents

Solid-state forms of relugolix Download PDF

Info

Publication number
CA3145993A1
CA3145993A1 CA3145993A CA3145993A CA3145993A1 CA 3145993 A1 CA3145993 A1 CA 3145993A1 CA 3145993 A CA3145993 A CA 3145993A CA 3145993 A CA3145993 A CA 3145993A CA 3145993 A1 CA3145993 A1 CA 3145993A1
Authority
CA
Canada
Prior art keywords
relugolix
anhydrous
solvent
dmf
dcm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3145993A
Other languages
English (en)
French (fr)
Inventor
Nicholas PASCHALIDES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlan Smith Ltd
Original Assignee
Johnson Matthey PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey PLC filed Critical Johnson Matthey PLC
Publication of CA3145993A1 publication Critical patent/CA3145993A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/03—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3145993A 2019-08-02 2020-07-31 Solid-state forms of relugolix Pending CA3145993A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882297P 2019-08-02 2019-08-02
US62/882,297 2019-08-02
PCT/US2020/044553 WO2021026011A1 (en) 2019-08-02 2020-07-31 Solid-state forms of relugolix

Publications (1)

Publication Number Publication Date
CA3145993A1 true CA3145993A1 (en) 2021-02-11

Family

ID=72145496

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3145993A Pending CA3145993A1 (en) 2019-08-02 2020-07-31 Solid-state forms of relugolix

Country Status (8)

Country Link
US (1) US20230374030A1 (https=)
EP (1) EP4007760A1 (https=)
JP (1) JP2022542159A (https=)
KR (1) KR20220047972A (https=)
CN (1) CN114174302A (https=)
BR (1) BR112022001002A2 (https=)
CA (1) CA3145993A1 (https=)
WO (1) WO2021026011A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
WO2021031148A1 (zh) * 2019-08-21 2021-02-25 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
CN114031626A (zh) * 2021-12-09 2022-02-11 成都科圣原医药科技有限公司 一种瑞卢戈利的合成方法
WO2025037218A1 (en) * 2023-08-11 2025-02-20 Glenmark Life Sciences Limited Crystalline solvate of relugolix and a process for its preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300935B2 (en) * 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
AR092707A1 (es) * 2012-09-28 2015-04-29 Takeda Pharmaceuticals Co Metodo de produccion de derivado de tienopirimidina
TWI744224B (zh) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 固形製劑
US11306104B2 (en) * 2018-03-14 2022-04-19 Teva Pharmaceuticals International Gmbh Solid state forms of Relugolix
EP3666776A1 (en) * 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist

Also Published As

Publication number Publication date
KR20220047972A (ko) 2022-04-19
BR112022001002A2 (pt) 2022-04-12
EP4007760A1 (en) 2022-06-08
WO2021026011A1 (en) 2021-02-11
US20230374030A1 (en) 2023-11-23
JP2022542159A (ja) 2022-09-29
CN114174302A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
AU2025203781B2 (en) Crystalline forms of cftr modulators
CA3145993A1 (en) Solid-state forms of relugolix
CN117980298A (zh) 作为kif18a抑制剂的化合物
WO2022121670A1 (zh) Tolebrutinib的晶型及其制备方法和用途
CN115385894A (zh) 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
JP2022522395A (ja) 選択的エストロゲン受容体分解剤の新規な塩
US12030886B2 (en) Form of ponatinib
US12559478B2 (en) Co-crystal forms of selinexor
US11655256B1 (en) Processes for making a solid-state form of relugolix
US11306062B2 (en) Forms of fedratinib dihydrochloride
EP4448516A1 (en) Crystalline forms of a ripk1 inhibitor
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
KR101285050B1 (ko) 결정형 1Ｈ-이미다조[4,5-ｂ]피리딘-5-아민,7-[5-[(시클로헥실메틸아미노)-메틸]-1Ｈ-인돌-2-일]-2-메틸, 설페이트 (1:1), 삼수화물 및 이의 약학적 용도
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
WO2020072870A1 (en) Co-crystal forms of baricitinib
US20230159468A1 (en) Novel forms of pracinostat dihydrochloride
WO2024157139A1 (en) Polymorphic forms of savolitinib
WO2019070698A1 (en) Novel forms of ibrutinib
US20210246159A1 (en) Novel form of bardoxolone methyl
WO2023180537A1 (en) Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases
WO2022143897A1 (zh) A-失碳-5α雄甾烷化合物的多晶型物
WO2019195827A1 (en) Novel form of ibrutinib
WO2019209908A1 (en) Crystalline forms of dasatinib
JP2020513006A (ja) アファチニブジマレアートの新規形態

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260116